Answers are grounded in this paper and cite their sources.
Cancer can recur when cells that survive dissemination or treatment resume growth. A smaller metastatic burden can reflect slower proliferation, greater immune clearance or fewer viable residual cells. We review long non-coding RNA (lncRNA) perturbation studies that separate these effects. In breast cancer models, NR2F1-AS1 increases NR2F1 translation. This favors dissemination but limits proliferation in the lung. BORG promotes outgrowth from latency through tripartite motif-containing protein 28 (TRIM28), while MALAT1 helps emerging metastases survive immune attack. These experiments illustrate why a change in lesion burden can point to different interventions. The same question arises in drug-tolerant persistence (DTP). Drug-response studies identify candidate RNAs, but few test whether the RNA is needed once reversibly tolerant cells have formed. For relapse prevention, experiments need to count viable residual cells separately from growing lesions and establish when the RNA interaction matters.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: